Compounds > nooglutil
Page last updated: 2024-11-07

nooglutil

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

nooglutil: RN refers to (L)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID147523
SCHEMBL ID2497750
MeSH IDM0181978

Synonyms (22)

Synonym
brn 4200454
n-5-(hydroxynicotinoyl)-l-glutamic acid
l-glutamic acid, n-((5-hydroxy-3-pyridinyl)carbonyl)-
onk-10
nooglutil
(2s)-2-[(5-hydroxypyridine-3-carbonyl)amino]pentanedioic acid
unii-09um5jos3w
112193-35-8
09um5jos3w ,
AKOS013164096
n-5-(hydroxynicotinoyl)-l-glutamic acid [who-dd]
onk10
nooglutyl
(2s)-2-((5-hydroxypyridine-3-carbonyl)amino)pentanedioic acid
SCHEMBL2497750
n-(5-oxynicotinoyl)-l-glutamic acid
n-(5-hydroxynicotinoyl)-l-glutamic acid
DTXSID90920687
(5-hydroxynicotinoyl)-l-glutamic acid
XFZGYOJFPGPYCS-QMMMGPOBSA-N
Q15425767
(2s)-2-[(5-hydroxypyridin-3-yl)formamido]pentanedioic acid

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" The ONG concentration decay had a two-phase character in both rats and rabbits, so that the pharmacokinetic profiles were fitted to a biexponential equation of the two-compartment model."( [Pharmacokinetics of n-(5-oxynicotinoyl)-L-glutamic acid calcium salt upon bolus administration in rats and rabbits: interspecies extrapolation].
Dolgova, GV; Dovzhenko, SA; Firsov, AA; Kiselev, AV; Kobrin, MB; Pomerantseva, TIa; Portnoĭ, IuA; Stovbun, SV, 2010)		0.36

Bioavailability

ExcerptReferenceRelevance
"Comparative study of the main pharmacokinetic characteristics and evaluation of the bioavailability of two experimental tablet forms of the new nootropic nooglutil in relation to the substance of the drug were conducted on rabbits."( [The bioavailability of tableted drug forms of the new Russian nootropic preparation nooglutil in rabbits].
Chesnokova, EA; Kartashov, VS; Sariev, AK; Smirnov, LD; Zherdev, VP, )		0.55
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's3 (50.00)18.2507
2000's1 (16.67)29.6817
2010's2 (33.33)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 23.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index23.17 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index23.28 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (23.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other15 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
3,4-dihydroxyphenylacetic acid
3,4-Dihydroxyphenylacetic Acid: A deaminated metabolite of LEVODOPA.. (3,4-dihydroxyphenyl)acetic acid : A dihydroxyphenylacetic acid having the two hydroxy substituents located at the 3- and 4-positions. It is a metabolite of dopamine.. dihydroxyphenylacetic acid : A dihydroxy monocarboxylic acid consisting of phenylacetic acid having two phenolic hydroxy substituents.		1.9810catechols;
dihydroxyphenylacetic acid		human metabolite
clonidine
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.		1.9710clonidine;
imidazoline
diazepam
Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.		2.01101,4-benzodiazepinone;
organochlorine compound		anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic
meclofenoxate
Meclofenoxate: An ester of DIMETHYLAMINOETHANOL and para-chlorophenoxyacetic acid.		1.9710monocarboxylic acid
piracetam
Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.		1.9710organonitrogen compound;
organooxygen compound
spiperone
Spiperone: A spiro butyrophenone analog similar to HALOPERIDOL and other related compounds. It has been recommended in the treatment of SCHIZOPHRENIA.. spiperone : An azaspiro compound that is 1,3,8-triazaspiro[4.5]decane which is substituted at positions 1, 4, and 8 by phenyl, oxo, and 4-(p-fluorophenyl)-4-oxobutyl groups, respectively.		7.0110aromatic ketone;
azaspiro compound;
organofluorine compound;
piperidines;
tertiary amino compound		alpha-adrenergic antagonist;
antipsychotic agent;
dopaminergic antagonist;
psychotropic drug;
serotonergic antagonist
metergoline
Metergoline: A dopamine agonist and serotonin antagonist. It has been used similarly to BROMOCRIPTINE as a dopamine agonist and also for MIGRAINE DISORDERS therapy.. metergoline : An ergoline alkaloid that is the N-benzyloxycarbonyl derivative of lysergamine. A 5-HT2 antagonist. Also 5-HT1 antagonist and 5-HT1D ligand. Has moderate affinity for 5-HT6 and high affinity for 5-HT7.		1.9710carbamate ester;
ergoline alkaloid		dopamine agonist;
geroprotector;
serotonergic antagonist
scopolamine hydrobromide
[no description available]		1.9710
sodium oxybate
Sodium Oxybate: The sodium salt of 4-hydroxybutyric acid. It is used for both induction and maintenance of ANESTHESIA.		1.9810
ConditionIndicatedRelationship StrengthStudiesTrials
Body Weight, Fetal
[description not available]		02.0710
Pregnancy
The status during which female mammals carry their developing young (EMBRYOS or FETUSES) in utero before birth, beginning from FERTILIZATION to BIRTH.		02.4220
Drug Withdrawal Symptoms
[description not available]		02.0110
Substance Withdrawal Syndrome
Physiological and psychological symptoms associated with withdrawal from the use of a drug after prolonged administration or habituation. The concept includes withdrawal from smoking or drinking, as well as withdrawal from an administered drug.		02.0110
Delayed Effects, Prenatal Exposure
[description not available]		01.9810
Academic Disorder, Developmental
[description not available]		01.9710
Age-Related Memory Disorders
[description not available]		01.9710
Learning Disabilities
Conditions characterized by a significant discrepancy between an individual's perceived level of intellect and their ability to acquire new language and other cognitive skills. These may result from organic or psychological conditions. Relatively common subtypes include DYSLEXIA, DYSCALCULIA, and DYSGRAPHIA.		01.9710
Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.		01.9710